Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Xencor Inc (XNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,858,522
  • Shares Outstanding, K 56,353
  • Annual Sales, $ 40,600 K
  • Annual Income, $ -70,410 K
  • 60-Month Beta 1.35
  • Price/Sales 45.77
  • Price/Cash Flow N/A
  • Price/Book 3.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.45
  • Number of Estimates 4
  • High Estimate -0.33
  • Low Estimate -0.58
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.60 +10.95%
on 05/02/19
36.96 -11.15%
on 05/10/19
+1.01 (+3.17%)
since 04/24/19
3-Month
27.75 +18.34%
on 03/14/19
36.96 -11.15%
on 05/10/19
+1.21 (+3.83%)
since 02/22/19
52-Week
27.75 +18.34%
on 03/14/19
48.38 -32.12%
on 09/14/18
-4.70 (-12.52%)
since 05/24/18

Most Recent Stories

More News
Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases,...

XNCR : 32.84 (-0.42%)
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 220.93% and 86.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 32.84 (-0.42%)
Xencor: 1Q Earnings Snapshot

MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Thursday reported first-quarter net income of $80 million, after reporting a loss in the same period a year earlier.

XNCR : 32.84 (-0.42%)
Xencor Reports First Quarter 2019 Financial Results

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases,...

XNCR : 32.84 (-0.42%)
Xencor to Present at Upcoming Investor Conferences

Xencor, Inc.(NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases,...

XNCR : 32.84 (-0.42%)
Xencor Doses First Patient in Phase 1 Study of XmAb(R)23104 for the Treatment of Patients with Advanced Solid Tumors

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases,...

XNCR : 32.84 (-0.42%)
Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019

Xencor, Inc.(NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases,...

XNCR : 32.84 (-0.42%)
Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb(R)14045

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases,...

XNCR : 32.84 (-0.42%)
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program

-- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates --

ALPMF : 13.7600 (+5.85%)
XNCR : 32.84 (-0.42%)
Xencor to Participate in Upcoming Investor Conferences

Xencor, Inc.(NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases,...

XNCR : 32.84 (-0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade XNCR with:

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

2nd Resistance Point 33.73
1st Resistance Point 33.28
Last Price 32.84
1st Support Level 32.51
2nd Support Level 32.18

See More

52-Week High 48.38
Fibonacci 61.8% 40.50
Fibonacci 50% 38.07
Fibonacci 38.2% 35.63
Last Price 32.84
52-Week Low 27.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar